Navigation Links
Collagen Meniscus Implant

ProductsCollagen Meniscus Implant
Company ReGen Biologics
Item Collagen Meniscus Implant
Features 
  • A type I collagen implant designed for patients with an irreparable meniscus tear or loss of meniscus tissue
  • The purpose of the CMI is to assist patients to regain mobility and return to a more vigorous lifestyle, while forestalling or minimizing degenerative joint disease.
  • Assists the body to generate new tissue, which replaces the damaged meniscus tissue removed by the surgeon.
  • The result is designed to provide patients with increased mobility and a return to a more active lifestyle.
    • Description The Collagen Meniscus Implant (CMI) is a type I collagen implant designed for patients with an irreparable meniscus tear or loss of meniscus tissue, typically through an arthroscopic partial meniscectomy procedure. The purpose of the CMI is to assist patients to regain mobility and return to a more vigorous lifestyle, while forestalling or minimizing degenerative joint disease. The Collagen Meniscus Implant is a method of regenerating meniscus tissue using the body's own healing process. A next generation approach to tissue repair, the CMI assists the body to generate new tissue, which replaces the damaged meniscus tissue removed by the surgeon. The result is designed to provide patients with increased mobility and a return to a more active lifestyle. The CMI is a resorbable type I collagen scaffold designed to minimize progressive degenerative changes in the knee after a partial meniscectomy by providing an alternative to the permanent loss of meniscus tissue. The CMI is similar to the natural shape of the meniscus and it is made of highly purified collagen, the most commonly found protein in the body. In cases where meniscus tissue cannot be repaired by suturing, the damaged tissue is removed and the CMI is sutured in place filling the defect where tissue is missing. Once sutured in place, the CMI provides a matrix into which the body's own cells may begin to move or migrate. New meniscus tissue is formed as these cells migrate and multiply. As this tissue regeneration takes place, the CMI is absorbed by the body. The regenerated tissue has the potential to restore function, reduce pain, and possibily suspend the degenerative process that begins with the loss of meniscus tissue. The CMI is made of type I collagen and it is a biocompatible, bioresorbable material that is designed to provide a scaffold for tissue growth when implanted in the knee. The surgeon sutures the CMI into the area where the meniscus tissue is missing. Once implanted, the CMI's highly porous matrix allows cellular ingrowth from the patient's own cells. This process regenerates meniscus tissue which provides the potential for restoring function, reducing pain and possibly arresting the degenerative process that begins with the loss of meniscus tissue.
    Info ReGen Biologics
    Customer Service: (201) 651-5140
    Web site: http://www.regenbio.com

    Related medicine products :

    1. Temporary Collagen Plugs
    2. Ultrafoam Collagen Sponge
    3. UltraPlug Collagen Absorbably Punctal Plugs
    4. INSTAT Collagen Absorbable Hemostat
    5. Pelvicol Acellular Collagen Matrix (Continence)
    6. Contigen Bard Collagen Implant
    7. Pelvicol® Acellular Collagen Matrix
    8. PelviSoft® Acellular Collagen BioMesh
    9. Hydrix XM Collagen Matrix
    10. Zyderm® and Zyplast® Injectable Collagen Implants
    11. CosmoDerm®and CosmoPlast® Collagen Replacement Therapy®
    ...ecord streamlines patient information management a...ion. A flexible and easily customizable solution, ...ial benefits. HealthMatics EHR organizes communica... with outside practitioners. It also manages order...
    ...ded model EMR system designed for creating and sto...-line simultaneously. Designed by a multi-talented... engineers, meridianEMR combines the power of Java...at provides physicians with:, Our powerful EMR ...
    ..., ER/Trauma, ICC/CCU, woundcare and burn centers r..., plus consistent high quality for outstanding bar...rile Singles deliver all that and more. Their smoo...The gloves are powder-free with a special design t...
    ...s become even better. Polymed® TLC latex exami...Polymed with the exciting addition of vitamin E. V...are vital to healthy skin. Polymed TLC gloves are ...ential for latex sensitization. The lightly textur...
    Medicine Products:
    (Date:9/5/2008)...a nonprofit organization,devoted to improving publ...e launch of a new FDA Web site created to help the...er (DTC) advertising of prescription,medications. ...ising," is,hosted by the FDA,s Center for Drug Eva...in partnership with EthicAd. For details, visit, h...
    (Date:9/5/2008)...site shouldn,t overreact or stop taking them , ....S. Food and Drug Administration has started listi...tial safety issues, the agency said Friday. , ... we have begun analysis to determine whether there...ion," Dr. Gerald Dal Pan, director of the FDA,s Of...
    (Date:9/4/2008)...- A groundbreaking program,dealing with the deteri...en, their shorter life spans, unmet gender specifi...Wednesday, September 17 at White Plains,Hospital. ...estchester,medical and psychiatric societies will ...el Tiger, Ph.D., Dr. Legatto, an internationally ...
    (Date:9/4/2008)... shortchanging their golden years by tapping into ...y of Illinois expert who has studied the federal r... than three of every four Americans trim their mon...enefits early, a choice many might forego if they ...uences, law professor Richard L. Kaplan says. , ...
    Breaking Medicine News(10 mins):Health News:Prescription Drug Advertising Subject of New FDA Web Site for Consumers 2Health News:FDA to List Drugs Under Review for Safety Issues 2Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3
    ...bout one percent of the total general population, ... and may be associated with various// types of can...edicine. Published in the December 6 Journal of t...he study looked for the presence and rate of BRCA ...
    ...increase since 1999 leaving the UK health departme...mpulsory recycling policy and composting bins are ...opulation. John Davison of the National Pest Tech...said: "It's a grave problem." "The way this is gr...
    ...being safer adults then children with lower intell...d intelligence with adult injury rates.// Debbie...d colleagues studied 11,282 people in Scotland who...evelopment study in the 1950s and 1960s, reported ...
    ...leased by Gov. Arnold Schwarzenegger recently, wor...with a double benefit - to their// health and weal...iums which will be exempted from tax. The proposa... ensure that heath insurance is reachable to the a...
    Other Medicine News:Health News:Cancer Gene Mutations Not Uncommon in General Population 2
    (Date:9/3/2008)...estion Asked. Wrong Children Studied. Wrong,Conclu...Newswire/ -- A Centers for Disease,Control and Pre... no link,between the MMR vaccine and autism. The N...oes nothing to dispel the growing public concern o... questions concerning design,and methodology., Fo...
    (Date:9/3/2008)...w up results from chronically infected Hepatitis C...a obtained earlier in 2008, - Study is the first... antiviral effect of therapeutic Hepatitis ...support move into a second generation, vaccine fo...through TLR activati...
    (Date:9/3/2008)..., Sept. 3 /- Panacea Pharmaceuticals,...Number 7,413,737 covering,antibodies against human...,proprietary human cancer biomarker and therapeuti...boration with the Massachusetts Institute of,Techn...ights to this patent,for development of human canc...
    (Date:9/3/2008)...perations, Updates Zingo Launch Progress and Adlea... Conference Call Today at 11:30 am ET...e-FirstCall/ -- Anesiva,Inc. (Nasdaq: ANSV ) ann...rations to focus on commercial and late-stage prod...specialty pharmaceutical pain management,company. ...
    Breaking Medicine Technology:CDC Misses Target With Flawed MMR/Autism Study 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Bright Medical Associates Selects InteGreat EHR for Ease of Use 7934 1Bright Medical Associates Selects InteGreat EHR for Ease of Use 7934 2Bright Medical Associates Selects InteGreat EHR for Ease of Use 7934 3Emageon Names Chris E Perkins as Chief Operating Officer 7930 1Emageon Names Chris E Perkins as Chief Operating Officer 7930 2New study shows worlds protected areas threatened by climate change 7926 1New study shows worlds protected areas threatened by climate change 7926 2American Chemical Societys Weekly PressPac Dec 5 2007 1515 1American Chemical Societys Weekly PressPac Dec 5 2007 1515 2American Chemical Societys Weekly PressPac Dec 5 2007 1515 3American Chemical Societys Weekly PressPac Dec 5 2007 1515 4American Chemical Societys Weekly PressPac Dec 5 2007 1515 5American Chemical Societys Weekly PressPac Dec 5 2007 1515 6American Chemical Societys Weekly PressPac Dec 5 2007 1515 7American Chemical Societys Weekly PressPac Dec 5 2007 1515 8American Chemical Societys Weekly PressPac Dec 5 2007 1515 9
    ...s--(BUSINESS WIRE)--Apr 3, 2007 - Repros,Therapeut...f a U.S.,Phase 2 study of Proellex(TM), an oral dr...fibroids. This study suggests that,treatment with ...cant improvement in symptoms associated with uteri...y Details and Results , This 12 week, double-blind...
    ...O, Calif., April 03, 2007,/PRNewswire-FirstCall/ -...d results from its second multi-center Phase 2 tri... evaluated escalating doses,of the immunotherapy i...rostate cancer (HRPC). Additional follow-up of,the...ble to that,being employed in the company,s ongoin...
    Other Medicine Technology:Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 2Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 3